Trial Summary
What is the purpose of this trial?
The objective of the BASIS R34 pilot study is to test the impact of eBASIS in a randomized controlled trial (RCT). Consistent with IMPACT's IQM, the study tests effects of eBASIS on treatment fidelity and youth outcomes, compared to a digitally delivered control (N=32 clinicians; 96 clients). A well-established EBP (Cognitive Behavioral Therapy Plus), will be a focus of the investigation, which eligible participants will already be signed up to receive.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
How is the eAttention Control, eBASIS treatment different from other mental health treatments?
The eAttention Control, eBASIS treatment is unique because it focuses on expanding access to evidence-based psychotherapy, particularly for underserved populations like rural veterans, by using specialized implementation and dissemination programs to improve access to known effective therapies.12345
Research Team
Aaron Lyon, PhD
Principal Investigator
University of Washington
Eligibility Criteria
This trial is for clinicians and their clients involved in a mental health program called Cognitive Behavioral Therapy Plus. It's designed to see if an electronic tool, eBASIS, helps with treatment compared to a digital control. There are 32 clinicians and 96 clients participating.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Preparation/Adoption
Providers receive pre-training experiences designed to prepare them for the implementation of evidence-based practices.
Action Implementation
Providers engage in the implementation of eBASIS, focusing on improving attitudes, subjective norms, and self-efficacy.
Follow-up
Participants are monitored for changes in attitudes, self-efficacy, and implementation outcomes.
Treatment Details
Interventions
- eAttention Control (Behavioral Intervention)
- eBASIS (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor
Dr. Timothy H. Dellit
University of Washington
Chief Executive Officer since 2023
MD from University of Washington
Dr. Anneliese Schleyer
University of Washington
Chief Medical Officer since 2023
MD, MHA
University of Kansas
Collaborator
Lynne A. Bui
University of Kansas
Chief Medical Officer since 2017
MD from the David Geffen UCLA School of Medicine, BA in Molecular and Cell Biology from University of California, Berkeley
Randy Milby
University of Kansas
Chief Executive Officer since 2017
BS in Pharmacy from The University of Kansas, MBA in Finance/Marketing from Washington University in St. Louis – Olin Business School
National Institute of Mental Health (NIMH)
Collaborator
Dr. Joshua A. Gordon
National Institute of Mental Health (NIMH)
Chief Executive Officer since 2016
MD, PhD
Dr. Shelli Avenevoli
National Institute of Mental Health (NIMH)
Chief Medical Officer
PhD